Nautilus Biotechnolgy, Inc. (NAUT)

Nautilus Biotechnology's stock has experienced several notable events in the past six months. The company reported its Q3 2025 earnings, posting an EPS of -$0.11, which exceeded analysts' expectations, leading to a pre-market stock surge. Nautilus Biotechnology announced the successful installation and testing of its first external field evaluation unit at the Buck Institute for Research on Aging. Nautilus Biotechnology announced a collaboration with Weill Cornell Medicine-Qatar and The Michael J. Fox Foundation to advance single-molecule proteomics research in Parkinson's disease. The company launched an Early Access Program for its novel single-molecule proteomics platform, starting with a validated tau proteoforms assay. Nautilus Biotechnology announced it would report financial results for the fourth quarter and full year 2025 before market open on February 26, 2026. Over the last 12 months, the stock price increased, but in the past month, it decreased. The stock traded between a 52-week high of $2.54 and a low of $0.62.

Nautilus Biotechnology, Inc. is currently a pre-revenue, development-stage company, with its commercial launch anticipated in late 2026. As such, there is no established demand seasonality for its products and services at this time. The company is focused on platform validation and preparation for commercialization.

Nautilus Biotechnology, Inc. is a development-stage life sciences company focused on revolutionizing proteomics by developing a platform technology to quantify and unlock the complexity of the proteome. The company operates within the Healthcare sector, specifically in the Biotechnology & Medical Research and Life Sciences Tools and Services industries. Its primary offering is the proprietary Nautilus Platform, an end-to-end solution that includes instruments, consumables, and software for proteome analysis. Key products and services include a proteome analysis system, reagent kits, integrated software, and targeted proteoform assays. The company's mission is to democratize access to the proteome and enable fundamental advancements across human health and medicine.

Nautilus Biotechnology, Inc. is headquartered in Seattle, Washington, with its research and development operations maintaining a strong presence in San Carlos, California. The company has expressed an aim to expand its presence into international markets, particularly in Europe and Asia.

Nautilus Biotechnology's brand reputation in the past year has been mixed. While the company is pioneering a revolutionary proteomics platform, analysts currently rate the stock with a "Sell" consensus. The installation of the first external field evaluation unit at the Buck Institute for Research on Aging in November 2025, which produced highly reproducible data, is a significant step towards market readiness and external validation. Partnerships, such as the one with Weill Cornell Medicine-Qatar and The Michael J. Fox Foundation for Parkinson's disease research, validate the company's technology and potential impact. The publication of its first scientific manuscript demonstrating the Iterative Mapping method for measuring proteoforms with unprecedented resolution has enhanced its scientific credibility. The launch of an early access program for its platform, starting with a tau proteoforms assay, indicates tangible progress towards commercialization. Despite these positive developments, the company remains pre-revenue, and its platform is not yet commercially available, which contributes to a "high-risk, high-reward" perception.

Nautilus Biotechnology, Inc. has a significant portion of its shares held by institutional and individual owners. As of September 2025, 66 institutional firms held 57.85 million shares. Major institutional owners include AH Capital Management, L.L.C., Perceptive Advisors Llc, Cercano Management LLC, Madrona Venture Group, LLC, Vanguard Group Inc, Comprehensive Financial Management LLC, Amazon Com Inc, Clarius Group, LLC, and Renaissance Technologies Llc. Among individual owners, co-founder and Chief Scientist Parag Mallick holds the most shares, and co-founder and CEO Sujal Patel also holds a significant stake. Individual insiders and venture capital/private equity firms together hold over 62% of the outstanding shares.